Back
Addus HomeCare 10K Form
Sell
44
ADUS
Addus HomeCare
Last Price:
128.81
Seasonality Move:
9.72%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-07 | 10Q | ADUS/Addus HomeCare Quarterly |
2023-10-31 | 10Q | ADUS/Addus HomeCare Quarterly |
2023-08-01 | 10Q | ADUS/Addus HomeCare Quarterly |
2023-05-02 | 10Q | ADUS/Addus HomeCare Quarterly |
2022-11-01 | 10Q | ADUS/Addus HomeCare Quarterly |
2022-08-02 | 10Q | ADUS/Addus HomeCare Quarterly |
Receive ADUS News And Ratings
See the #1 stock for the next 7 days that we like better than ADUS
ADUS Financial Statistics
Sales & Book Value
Annual Sales: | $1.06B |
---|---|
Cash Flow: | $17.74M |
Price / Cash Flow: | 20.83 |
Annual Sales: | $50.93 |
Price / Book: | 2.48 |
Profitability
EPS (TTM): | 4.22000 |
---|---|
Net Income (TTM): | $68.9M |
Gross Margin: | $339.88M |
Return on Equity: | 9.3% |
Return on Assets: | 6.73% |
Addus HomeCare Earnings Forecast
Key Addus HomeCare Financial Ratios
- The Gross Profit Margin over the past 17 years for ADUS is 32.10%.
- The Selling, General & Administrative Expenses for ADUS have been equal to 22.18% of Gross Profit Margin.
- The Research & Development expenses have been 0.00% of Revenue.
- The Interest Expense is 17.77% of Operating Income.
- The Net Earning history of ADUS is 5.91% of Total Revenues.
- Per Share Earnings over the last 17 years have been positive in 11 years.
Addus HomeCare Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Health Care Providers & Services |
Sector: | Health Care |
Current Symbol: | ADUS |
CUSIP: | 006739 |
Website: | addus.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 2 |
Quick Ratio: | 1.92 |
Price-to-Earnings
Trailing P/E Ratio: | 32.97 |
---|---|
Forward P/E Ratio: | 21.09 |
ADUS Technical Analysis vs Fundamental Analysis
Sell
44
Addus HomeCare (ADUS)
is a Sell
Is Addus HomeCare a Buy or a Sell?
-
Addus HomeCare stock is rated a Sell
The current Addus HomeCare [ADUS] share price is $126.27. The Score for ADUS is 44, which is 12% below its historic median score of 50, and infers higher risk than normal.